<<Corp: I have not seen any posting implying that Repros would not be able to get an IND thru the FDA for Anemia.>>
Thomas, you must be suffering from memory loss. You participated in the dialogue on DewD's board which he started with the following words:
"RPRX off 20% – What stands out in today’s PR is the FDA request that the company submit a new IND for the anemia indication. The need for a new IND adds a layer of perceived uncertainty to this program."
(I've already pointed out the irony that the guy whose tag line derides the efficent markets hypothesis - very reasonably in the small biotech space - should use a market move to justify a negative comment.)
And if you want to split hairs and pretend that he was not implying any risk that the IND will not be accepted, I'd help you recall that he drew an analogy between RPRX and COR, and among other things wrote
"COR already had human data in the ADHD indication, but the FDA rejected the IND anyhow."
Although most of his posts on Dec 4 and subsequently have proceeded by subtle Socratic innuendo - " you tell me why FDA wants a separate IND" - one underlying worst-case threat that he implies is indeed that RPRX won't get the anemia IND.
One more time, RPRX has a mkt cap of ~$100mm and a high probability of Proellex success in a major group of indications. Bad-mouthing the investment at these prices is IMO bad judgment.
Market Data 
Markets 
